INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2010

Inoperable pancreatic cancer patients who chose chemotherapy survived significantly longer with better quality of life than those choosing enzyme therapy.

Researchers compared outcomes in 55 patients with inoperable pancreatic cancer who elected either gemcitabine-based chemotherapy (n = 23) or enzyme treatment including pancreatic enzymes, nutritional supplements, detoxification, and an organic diet (n = 32). Median survival was 14 months for the chemotherapy group versus 4.3 months for the enzyme group, with an adjusted-mortality hazard ratio of 6.96 (P < .001) for enzyme therapy compared to chemotherapy. At 1 year, 56% of chemotherapy patients were alive compared with 16% of enzyme-therapy patients. Quality of life ratings were also significantly better in the chemotherapy group than in the enzyme-treated group (P < .01).

Shows an association, not proof of cause and effect.

Study type
Controlled observational study
Who was studied
55 patients with inoperable pancreatic cancer (23 chose chemotherapy, 32 chose enzyme therapy)
What was measured
Overall survival and quality of life

THE PAPER

Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.

Chabot JA, Tsai WY, Fine RL, Chen C, Kumah CK, Antman KA, Grann VR. J Clin Oncol, 2010.

PubMed 19687327 ↗DOI 10.1200/jco.2009.22.8429 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.